Third, although triple immunotherapy comprising an anti-PD-1 mAb, STING agonist, and anti-LAG-3 mAb demonstrated adequate biosafety in murine HCC models, further investigations are warranted to evaluate its efficacy, potential toxicities, and optimal dosage in human subjects. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.